POINT Biopharma Global Stock Forecast, Price & News

POINT Biopharma Global (NASDAQ:PNT) Frequently Asked Questions

Is POINT Biopharma Global a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" POINT Biopharma Global stock.
View analyst ratings for POINT Biopharma Global or view top-rated stocks.

What stocks does MarketBeat like better than POINT Biopharma Global?

Wall Street analysts have given POINT Biopharma Global a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but POINT Biopharma Global wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting POINT Biopharma Global?

POINT Biopharma Global saw a increase in short interest in September. As of September 30th, there was short interest totaling 1,280,000 shares, an increase of 52.7% from the September 15th total of 838,100 shares. Based on an average daily trading volume, of 168,300 shares, the short-interest ratio is currently 7.6 days. Currently, 1.8% of the shares of the stock are short sold.
View POINT Biopharma Global's Short Interest.

When is POINT Biopharma Global's next earnings date?

POINT Biopharma Global is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for POINT Biopharma Global.

How were POINT Biopharma Global's earnings last quarter?

POINT Biopharma Global Inc. (NASDAQ:PNT) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01.
View POINT Biopharma Global's earnings history.

What price target have analysts set for PNT?

3 equities research analysts have issued 1-year price objectives for POINT Biopharma Global's shares. Their forecasts range from $8.00 to $17.00. On average, they expect POINT Biopharma Global's share price to reach $12.50 in the next year. This suggests a possible upside of 56.8% from the stock's current price.
View analysts' price targets for POINT Biopharma Global or view top-rated stocks among Wall Street analysts.

Who are some of POINT Biopharma Global's key competitors?

Some companies that are related to POINT Biopharma Global include ACADIA Pharmaceuticals (ACAD), Prothena (PRTA), Agios Pharmaceuticals (AGIO), Emergent BioSolutions (EBS), PTC Therapeutics (PTCT), Sage Therapeutics (SAGE), Aurinia Pharmaceuticals (AUPH), OPKO Health (OPK), Arcus Biosciences (RCUS), Taro Pharmaceutical Industries (TARO), ChemoCentryx (CCXI), ALX Oncology (ALXO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Turning Point Therapeutics (TPTX).
View all of PNT's competitors.

What is POINT Biopharma Global's stock symbol?

POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."

How do I buy shares of POINT Biopharma Global?

Shares of PNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is POINT Biopharma Global's stock price today?

One share of PNT stock can currently be purchased for approximately $7.97.

How much money does POINT Biopharma Global make?

POINT Biopharma Global has a market capitalization of $718.27 million.

What is POINT Biopharma Global's official website?

The official website for POINT Biopharma Global is www.pointbiopharma.com.

Where are POINT Biopharma Global's headquarters?

POINT Biopharma Global is headquartered at 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116.